

# PUBLIC SUBMISSION

**As of:** 2/19/15 10:41 AM  
**Received:** February 09, 2015  
**Status:** Draft  
**Category:** Drug Industry - C0022  
**Tracking No.** 1jz-8h3t-n7co  
**Comments Due:** February 09, 2015  
**Submission Type:** Web

**Docket:** FDA-2014-N-1960

Agency Information Collection Activities; Proposed Collection; Comment Request; MedWatch: The Food and Drug Administration Medical Products Reporting Program

**Comment On:** FDA-2014-N-1960-0001

Agency Information Collection Activities; Proposed Collection; Comment Request; MedWatch: The Food and Drug Administration Medical Products Reporting Program

**Document:** FDA-2014-N-1960-DRAFT-0003

Comment from Linda Bowen, Sanofi

---

## Submitter Information

**Name:** Linda Bowen

**Organization:** Sanofi

---

## General Comment

See attached

---

## Attachments

Signed comment FDA-2014-N-1960



**09 February 2015**

Division of Dockets Management (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane, Room 1061  
Rockville, MD 20852

**Re: Docket No. FDA-2014-N-1960**

**Request for comments:** Agency Information Collection Activities; Proposed Collection; Comment Request; MedWatch: The FDA Medical Products Reporting Program

Dear Sir/Madam:

Reference is made to the Federal Register Notice of 11 December 2014 (79 FR 73591) announcing a call for comments on FDA's proposed collection of information on their Medical Products Reporting Program (MedWatch).

Sanofi, an integrated global healthcare leader that discovers, develops and distributes therapeutic solutions focused on patients' needs, appreciates the opportunity to provide feedback and offers the following:

**Comment 1:** Page 73594 Section B. Changes Proposed for Form FDA 3500; Page 73594 Section C. Changes Proposed for Form FDA 3500A; and Page 73595 Section D. Changes Proposed for Form FDA 3500B

We recommend the option of a check box for race/ethnicity **unknown**.

**Comment 2:**

We recommend an implementation date eighteen (18) months after publication of the finalized form.

Sincerely,

A handwritten signature in dark ink, appearing to read "Linda Bowen". The signature is fluid and cursive, with the first name "Linda" and last name "Bowen" clearly distinguishable.

*Linda Bowen, MS, RAC, FRAPS  
Head of U.S. Regulatory Policy and Intelligence*